Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Explore our marketplaces to find the right financial products for your needs. 11 best travel credit cards of March 2026 ...